Single, Dual & Triple Receptor Agonists

GLP-1s

GLP-1 products differ in the receptors they target — and therefore in how they work. Some act on a single pathway, while others combine two or three receptors, offering different mechanisms of action and different levels of weight-management support.

Product Comparison

Semaglutide, tirzepatide, and retatrutide are increasingly powerful metabolic medications that mimic gut hormones to regulate blood sugar, reduce appetite, and promote significant weight loss. They represent three progressive ‘generations’ of injectable treatments, with each targeting more hormone receptors than the last.

Product Semaglutide
GLP-1
 Tirzepatide
GLP-1 + GIP
 Retatrutide
GLP-1 + GIP + Glucagon
Receptor targets GLP-1 GLP-1 + GIP GLP-1 + GIP + Glucagon
Average weight reduction* 15–17% 20–22% Up to 24–28.7%

*Average weight reduction figures are drawn from clinical studies. Results vary between individuals.

GLP-1

GLP-1 is released from the intestines after eating.

What it does
  • •Slows stomach emptying
  • •Makes you feel full longer
  • •Reduces hunger and food noise
  • •Stimulates insulin release
  • •Reduces glucagon secretion
Result
  • Lower blood sugar
  • Smaller portions
  • Weight loss

GIP

GIP is another incretin hormone released after eating. For years scientists thought GIP was less useful because people with obesity or diabetes can become resistant to it. But when combined with GLP-1, it seems to become very powerful.

What it does
  • •Boosts insulin secretion
  • •May improve fat metabolism
  • •May reduce nausea from GLP-1s
  • •May enhance weight loss when paired with GLP-1
Result
  • Better blood sugar control.
  • Stronger weight loss than GLP-1 alone in many people.

Glucagon

Glucagon is very different. Normally, it is released when blood sugar is low. Its job is basically the opposite of insulin.

What it does
  • •Tells the liver to release stored glucose
  • •Increases energy expenditure
  • •Can increase fat oxidation (“fat burning”)
  • •May increase body temperature/metabolism
Result
  • Researchers discovered that combining glucagon activation with GLP-1 changes everything.
  • GLP-1 controls appetite and blood sugar while glucagon increases energy expenditure.
  • So together you may get: less eating, more calorie burning, potentially greater fat loss.
Beyond weight loss

Other Health Benefits

Tirzepatide, semaglutide, and retatrutide offer significant health benefits beyond weight reduction, including cardiovascular protection, improved blood sugar control, and reduced substance cravings. These groundbreaking medications are increasingly recognized for their systemic impacts on metabolic, cardiac, and neurological health.

Cardiovascular & Heart Health

01
Reduced Cardiac Events: Semaglutide and tirzepatide lower the combined risk of major adverse cardiovascular events—such as stroke, heart attack, and cardiovascular death—by up to 13% to 18%.
02
Blood Pressure Lowering: Clinical trials for retatrutide have shown significant reductions in systolic blood pressure.
03
Heart Failure & Stroke: These medications are associated with lower rates of heart failure.

Metabolic & Liver Health

01
Blood Sugar & Insulin Control: Originally developed for type 2 diabetes, these drugs stimulate insulin secretion when blood sugar is high and lower hemoglobin A1c levels, often putting pre-diabetes into remission.
02
Lipid Management: Studies demonstrate substantial reductions in triglycerides and non-HDL cholesterol.
03
Fatty Liver Disease: All three medications, particularly retatrutide due to its glucagon receptor activation, show remarkable promise in reducing excess liver fat.

Neurological & Anti-Consumption Effects

01
Rewiring Reward Pathways: By targeting the brain's reward centers, these drugs are being investigated as "anti-consumption" agents.
02
Reduced Addictive Behaviors: Observational data indicates spontaneous reductions in food cravings, alcohol consumption, nicotine addiction, and compulsive behaviors like compulsive gambling or uncontrollable shopping.

Chronic Disease & Inflammation

01
Pain Reduction: Weight-independent improvements in knee pain for patients suffering from debilitating osteoarthritis have been observed.
02
Sleep Apnea: Clinical data shows significant decreases in the apnea-hypopnea index, alleviating symptoms of obstructive sleep apnea.
03
Kidney Protection: Evolving evidence links GLP-1 and GIP receptor agonists to decreased risks of progressive kidney disease.

Pens vs Vials

Pens

  • •Easier to use
  • •More accurate dosing
  • •Lower contamination risk
  • •Better for beginners
  • •Usually more expensive

Vials

  • •Lower cost per mg
  • •Flexible dosing
  • •Require syringes
  • •Require correct reconstitution if powdered
  • •Higher risk of dosing mistakes or contamination if handled incorrectly
View products →